Key facts
- Institutional investors are showing increased confidence in GTX-102.
- This confidence has fueled optimism for Ultragenyx Pharmaceutical's prospects.
Institutional investors are demonstrating a growing level of confidence in GTX-102, a development that is positively impacting Ultragenyx Pharmaceutical (RARE). This increased institutional backing has led to heightened optimism surrounding the company's future outlook and potential.